Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis

被引：0
作者：
Teng-Kai Yang
Ya-Fang Yu
Chiao-Ling Tsai
Hsing-Ju Li
Po-Sheng Yang
Kai-Wen Huang
Jason Chia-Hsien Cheng
机构：
[1] Yonghe Cardinal Tien Hospital,Department of Surgery
[2] Fu-Jen Catholic University,School of Medicine, College of Medicine
[3] National Taiwan University College of Medicine,Graduate institute of Clinical Medicine
[4] National Taiwan University Hospital,Division of Radiation Oncology, Department of Oncology
[5] Mackay Memorial Hospital and Mackay Medical College,Department of General Surgery
[6] National Taiwan University Hospital,Department of Surgery
[7] National Taiwan University College of Medicine,Graduate Institute of Oncology
来源：
BMC Cancer | / 22卷
关键词：
Targeted therapy; Immunotherapy; Unresectable hepatocellular carcinoma; Systematic review; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 105 条
[1]  
Debela DT(2021)New approaches and procedures for cancer treatment: Current perspectives SAGE Open Medicine 9 20503121211034366-49
[2]  
Muzazu SG(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J Clin 71 209-51
[3]  
Heraro KD(2012)Combining immunotherapy and targeted therapies in cancer treatment Nat Rev Cancer 12 237-74
[4]  
Ndalama MT(2020)Targeted therapy for hepatocellular carcinoma Signal Transduct Target Ther 5 146-66
[5]  
Mesele BW(2015)Nanobody-based cancer therapy of solid tumors Nanomed (Lond) 10 161-90
[6]  
Haile DC(2020)Integrating immunotherapy and targeted therapy in cancer treatment: mechanistic insights and clinical implications Clin Cancer Res 26 5557-89
[7]  
Sung H(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-502
[8]  
Ferlay J(2019)Efficacy and safety of combination immunotherapy for malignant solid tumors: a systematic review and meta-analysis Crit Rev Oncol/Hematol 138 178-71
[9]  
Siegel RL(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial The Lancet 389 2492-301
[10]  
Laversanne M(2017)Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management Cancer Res 77 3666-905
12345678910